Elite Pharmaceuticals, Inc. (ELTP)
0.2891
-0.01
(-2.00%)
USD |
OTCM |
Aug 24, 16:00
Elite Pharmaceuticals EPS Diluted (Quarterly) : 0.0052 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0052 |
| March 31, 2026 | 0.0098 |
| December 31, 2025 | 0.0059 |
| September 30, 2025 | 0.0054 |
| June 30, 2025 | -0.0055 |
| March 31, 2025 | 0.0159 |
| December 31, 2024 | -0.0102 |
| September 30, 2024 | -0.0103 |
| June 30, 2024 | 0.0006 |
| March 31, 2024 | 0.0032 |
| December 31, 2023 | 0.0007 |
| September 30, 2023 | 0.0146 |
| June 30, 2023 | 0.0011 |
| March 31, 2023 | -0.0016 |
| December 31, 2022 | 0.0029 |
| September 30, 2022 | 0.0015 |
| June 30, 2022 | 0.0003 |
| March 31, 2022 | 0.0024 |
| December 31, 2021 | 0.0018 |
| September 30, 2021 | 0.0014 |
| June 30, 2021 | 0.0024 |
| March 31, 2021 | -0.0005 |
| December 31, 2020 | 0.002 |
| September 30, 2020 | 0.0014 |
| June 30, 2020 | 0.0011 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0011 |
| December 31, 2019 | -0.0022 |
| September 30, 2019 | -0.0019 |
| June 30, 2019 | -0.0015 |
| March 31, 2019 | -0.0032 |
| December 31, 2018 | -0.0033 |
| September 30, 2018 | -0.0032 |
| June 30, 2018 | -0.0021 |
| March 31, 2018 | -0.0035 |
| December 31, 2017 | -0.0014 |
| September 30, 2017 | -0.0028 |
| June 30, 2017 | -0.0026 |
| March 31, 2017 | -0.0035 |
| December 31, 2016 | 0.0001 |
| September 30, 2016 | -0.0015 |
| June 30, 2016 | -0.0014 |
| March 31, 2016 | 0.0318 |
| December 31, 2015 | -0.05 |
| September 30, 2015 | -0.0061 |
| June 30, 2015 | 0.0137 |
| March 31, 2015 | -0.01 |
| December 31, 2014 | -0.0034 |
| September 30, 2014 | -0.01 |
| June 30, 2014 | -0.01 |
| March 31, 2014 | -0.1875 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Nektar Therapeutics | -1.229 |
| Daré Bioscience, Inc. | -0.2003 |
| Eton Pharmaceuticals, Inc. | 0.3531 |
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 5.911M |
| Revenue (Quarterly) | 32.36M |
| Total Expenses (Quarterly) | 26.44M |
| Enterprise Value | 278.03M |
| Gross Profit Margin (Quarterly) | 40.61% |
| Profit Margin (Quarterly) | 18.27% |
| Earnings Yield | 9.10% |
| Operating Earnings Yield | 11.03% |
| Normalized Earnings Yield | 2.802 |